Abstract

Breast cancer is one of the most prevalent cancers worldwide usually treated with Tamoxifen. Tamoxifen resistance development is the most challenging issue in an initially responsive breast tumor, and mechanisms of resistance are still under investigation. The objective of this study is to develop and validate a selective, sensitive, and simultaneous high performance liquid chromatography–tandem mass spectrometry method to explore the changes in substrates and metabolites in supernatant media of developed Tamoxifen resistance MCF-7 cells. We focus on the determination of lactate, pyruvate, and L-glutamine which enables the tracking of changes in metabolic pathways as a result of the resistance process. Chromatographic separation was achieved within 3.5 min. using a HILIC column (4.6 × 100 mm, 3.5 µm particle size) and mobile phase of 0.05 M acetic acid–ammonium acetate buffer solution pH 3.0: Acetonitrile (40:60 v/v). The linear range was 0.11–2.25, 0.012–0.227, and 0.02–0.20 mM for lactate, pyruvate, and L-glutamine, respectively. Within- and between-run accuracy was in the range 98.94-105.50% with precision (CV, %) of ≤0.86%. The results revealed a significant increase in both lactate and pyruvate production after acquiring the resistant. An increase in L-glutamine levels was also observed and could be attributed to its over production or decline in its consumption. Therefore, further tracking of genes responsible of lactate, pyruvate, and glutamine metabolic pathways should be performed in parallel to provide in-depth explanation of resistance mechanism.

Highlights

  • Breast cancer (BC) is the most commonly diagnosed cancer globally with an estimation of 11.7% incidence of all cancer cases [1]

  • Different mechanisms have been suggested to explain the resistance including the loss of estrogen receptor (ER) expression [7], pharmacological tolerance and alteration in cellular kinase/transduction pathways [8], modification and alteration of some regulatory proteins [9], and increased expression of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) [10]

  • MCF-7 cells are characterized as an epithelial-like shape having strong cell-to-cell adherent properties and well-organized as monolayer [32]

Read more

Summary

Introduction

Breast cancer (BC) is the most commonly diagnosed cancer globally with an estimation of 11.7% incidence of all cancer cases [1]. The incidence and mortality among diagnosed cases in females worldwide were 24.2% and 15%, respectively [2]. Tamoxifen (TMX), the most well-known selective estrogen receptor modulator, has been utilized frequently as an adjuvant therapy for hormone receptor (HR)-positive BC [3]. It shows high efficacy in reducing the risk of BC recurrence and related mortality [4]. Different in vitro models have been investigated to further understand the resistance mechanisms. MCF-7 cell line, an ER-positive progesterone receptor (PR)-positive cell line, represents the most commonly used cell line in BC research for TMX resistance [12]

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call